Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...

A pioneer for organ donation, Allison had her liver, heart, lungs and kidney replaced over ... "rewriting the book" on how to survive with cystic fibrosis, said her father, David John.

This little Jewish boy’s story shows there is hope for cystic fibrosis sufferers A breakthrough for some who suffer with the inherited condition that causes sticky mucus to build up in the lungs ...

Throughout my childhood, I was thin and underweight thanks to cystic fibrosis. When my mother ... My first year of cross-country was very difficult. Since my lungs were in no way used to exercise, I ...

In this grim scenario, a lung transplant or access to genetic modulators are seen as Manuel's only hope, yet these options remain unattainable in Cuba. Beyond Manuel's case, the letter highlights the ...

Idiopathic Pulmonary fibrosis (IPF) is a subset of interstitial lung diseases, where in the normal ageing of lung is augmented. It is characterised by fibrosis of the lung architecture which ...